Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.
about
Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overviewInsights into the molecular etiology of exercise-induced inflammation: opportunities for optimizing performanceCombined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers.Deficient nitric oxide signalling impairs skeletal muscle growth and performance: involvement of mitochondrial dysregulation.A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy.Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP.Nitric Oxide Donor Molsidomine Positively Modulates Myogenic Differentiation of Embryonic Endothelial Progenitors.Requirement of inducible nitric oxide synthase for skeletal muscle regeneration after acute damage.Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal MusclesCell-matrix interactions in muscle disease.Nitric oxide in myogenesis and therapeutic muscle repair.Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy.Fat deposition and accumulation in the damaged and inflamed skeletal muscle: cellular and molecular players.The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.Autophagy as a new therapeutic target in Duchenne muscular dystrophyNitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice.Effect of Ibuprofen on Skeletal Muscle of Dysferlin-null Mice.Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice.
P2860
Q26849430-71732D2D-E928-4382-9EB8-B71ADD8FF03FQ28066359-DBF2491A-8FFE-48C7-8773-0CA9FFFE7C25Q33599468-DC6C0D79-E84F-41E0-90E0-4630026D3E7EQ34748781-9ED27CA4-B250-4505-8C50-77B76730612DQ35100498-CD021F3C-7629-4048-9FA3-5093852FCB7BQ35986842-71811291-AAC6-403C-8F6C-BEF14E39BFEDQ36043923-8E9D0FA6-DF98-43FF-BDBB-345308BEF5FAQ36168025-70620060-A605-4DE1-9934-0765A73AF4B9Q36593335-1391727D-837A-4B31-B5E9-0772D8FCB01EQ37589790-C824351B-DFCB-485C-BA79-D22B2CD705C8Q37944530-2A7696FB-AADE-4C0B-8E51-3D7107D8209BQ38028378-9C7FE80F-F463-4E29-91C8-89826A91FC76Q38246459-90D28554-2E2C-481B-BB6B-1CD429BA3FA1Q38411886-2B080BA0-CA50-4AA5-A005-5D465D41FB64Q38539938-FFF0F295-FE80-4BFD-A073-4571C3297884Q41869455-E74B4B92-5813-46C9-AA66-E26E6C5E86FCQ44291723-34B0041E-BEA9-471C-9481-E0FFE4C09146Q50128178-5819C460-4926-4A95-8A93-CAF58634087CQ52920061-405C9EA5-A8CD-45EA-84DC-D83847B4BE9F
P2860
Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Co-administration of ibuprofen ...... diate applicability to humans.
@ast
Co-administration of ibuprofen ...... diate applicability to humans.
@en
Co-administration of ibuprofen ...... diate applicability to humans.
@nl
type
label
Co-administration of ibuprofen ...... diate applicability to humans.
@ast
Co-administration of ibuprofen ...... diate applicability to humans.
@en
Co-administration of ibuprofen ...... diate applicability to humans.
@nl
prefLabel
Co-administration of ibuprofen ...... diate applicability to humans.
@ast
Co-administration of ibuprofen ...... diate applicability to humans.
@en
Co-administration of ibuprofen ...... diate applicability to humans.
@nl
P2860
P50
P1476
Co-administration of ibuprofen ...... ediate applicability to humans
@en
P2093
Dario Cattaneo
Roberta Buono
P2860
P304
P356
10.1111/J.1476-5381.2010.00809.X
P407
P50
P577
2010-07-01T00:00:00Z